About: Big pharma
MEP: A common EU tool to incentivise production and availability of orphan drugs
When it comes to rare diseases and 'orphan drugs', technology is there to support an “objective” EU tool that could provide the pharma industry with the necessary incentives to research and produce orphan drugs and simultaneously avoid exhausting ailing health systems, MEP Stelios Kympouropoulos told EURACTIV in an interview.
EU orphan drugs law and the emergence of SMEs
The legal framework provided by the current EU orphan drugs regulation has encouraged a number of small and medium sized companies (SMEs) to develop innovative technologies in the fight against rare diseases in Europe, stakeholders told EURACTIV.com.
Commission’s ‘risky’ move to re-visit orphan drugs regulation
The European Commission is expected to present by the end of July an evaluation study on the pros and cons of the application of orphan and paediatric regulations, which deal with a niche segment of rare diseases that affect fewer than five in 10,000 people.
German EU Presidency: Influenced by lobbyists?
Large lobbying associations have a strong influence on the German government and there are concerns that this might impact its EU Council presidency, which starts on 1 July, warned a study conducted by NGOs LobbyControl and Corporate Europe Observatory. EURACTIV Germany reports.
Drug industry reacts to Oxfam’s allegations of tax-dodging
Four of the world’s biggest pharma companies appear to hide their profits in tax havens, according to a report published by Oxfam on Tuesday (18 September). Businesses said they are in the clear.
EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation
The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.
Health care risks being forgotten in Brexit talks, industry warns
Health risks being forgotten in Brexit negotiations, potentially delaying the availability of new medicines and imposing large costs on manufacturers, public health leaders have warned.OpinionPromoted content
Drugs incentives have saved lives in Europe
Without strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.
Pharma boss: Targeting drugs won’t make healthcare systems more sustainable
“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.
Drugs firms call for phased transition of regulation after Brexit
Pharmaceutical companies called on Thursday (27 April) for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.
Fake drugs cost EU billions of euros, its health and its jobs
Counterfeit drugs are not only hazardous to health, they cost people their jobs too, a new EU study has revealed. But Germans in particular are willing to take risks. EURACTIV's partner Der Tagesspiegel reports.
Don’t be fooled by CETA: It’s a wolf in sheep’s clothing
In his State of the Union speech, Jean-Claude Juncker called the Canada-EU trade agreement the most progressive trade agreement the EU has ever negotiated. It actually poses a genuine threat to the health sector, argues Emma Woodford.